Floatz logo

IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS ICOS (INDUCIBLE T-CELL COSTIMULATORY, ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE, AILIM, CD278)) AND ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC

Undifferentiated Pleomorphic Sarcoma

Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Undifferentiated Pleomorphic Sarcoma cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Gdc-0449
National Cancer Institute (NCI)
Phase 1/2CCC
Cab-Axl-Adc
BioAtla, Inc.
Phase 1/2CCC
SAMROTAMAB VEDOTIN
AbbVie
Phase 1CC
Ipilimumab
Xencor, Inc.
Phase 1CC

View all 12 →

Same molecule, other indications

IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS ICOS (INDUCIBLE T-CELL COSTIMULATORY, ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE, AILIM, CD278)) AND ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC is also rated in:

triple-negative breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
47 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →